Nodriga (Dasatinib)

Dasatinib, the active ingredient in Nodriga, is a tyrosine kinase inhibitor presented as a 100 mg oral tablet for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nodriga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Dasatinib is used to target BCR‑ABL–driven leukemias, providing disease‑specific therapy for several phases of chronic myeloid leukemia and for Ph+ acute lymphoblastic leukemia.

- Chronic Myeloid Leukemia (chronic phase): improves hematologic, cytogenetic and molecular response in adult patients. - Chronic Myeloid Leukemia (accelerated phase): achieves disease control when used as first‑line or subsequent therapy. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia: provides targeted inhibition of BCR‑ABL as part of combination regimens.

Dasatinib may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often accompanied by loss of appetite. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or redness. - Myelosuppression: reduced white blood cells, platelets or red cells. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Pleural effusion: fluid accumulation around the lungs causing breathing difficulty. - Pulmonary hypertension: elevated blood pressure in lung arteries, potentially life‑threatening. - Severe bleeding: uncontrolled hemorrhage due to platelet dysfunction. - Cardiac dysfunction: reduced heart contractility or arrhythmias. - Severe infections: opportunistic infections requiring hospitalization. - Liver toxicity: significant elevation of liver enzymes or hepatic failure.

When prescribing Dasatinib, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: perform regular complete blood counts to detect cytopenias. - Assess cardiac function: obtain baseline echocardiogram and repeat if symptoms arise. - Evaluate liver function: check transaminases before treatment and periodically thereafter. - Avoid strong CYP3A4 inhibitors: concurrent use may increase dasatinib exposure. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Dasatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise dasatinib levels and risk of adverse effects. - Antacids containing aluminum or magnesium: reduce oral absorption of dasatinib. - Co‑administration with other BCR‑ABL inhibitors: may lead to additive toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower dasatinib exposure, reducing efficacy. - Proton pump inhibitors (e.g., omeprazole): may modestly affect gastric pH and absorption. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase bleeding risk when combined with dasatinib.